Comparing Pump With Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism
| Status: | Completed |
|---|---|
| Conditions: | Other Indications, Endocrine |
| Therapuetic Areas: | Endocrinology, Other |
| Healthy: | No |
| Age Range: | 7 - 70 |
| Updated: | 3/22/2019 |
| Start Date: | August 22, 2008 |
| End Date: | April 7, 2014 |
Comparing Pump vs. Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism
This study will evaluate the safety, biological activity, and pharmacokinetics of PTH
delivered by subcutaneous injection compared with an infusion pump. We anticipate pump
delivery of PTH will be more physiologic because it mimics normal parathyroid gland secretion
of PTH. We expect that pump delivery will simultaneously normalize blood and urine calcium,
phosphorus and magnesium levels with minimal or no fluctuations throughout the day. Pump
therapy will require lower PTH doses and should normalize markers of bone turnover. We expect
the improved metabolic control during pump therapy will be especially evident in patients
with more severe forms of hypoparathyrodism where there is an unmet need for improved
therapy.
delivered by subcutaneous injection compared with an infusion pump. We anticipate pump
delivery of PTH will be more physiologic because it mimics normal parathyroid gland secretion
of PTH. We expect that pump delivery will simultaneously normalize blood and urine calcium,
phosphorus and magnesium levels with minimal or no fluctuations throughout the day. Pump
therapy will require lower PTH doses and should normalize markers of bone turnover. We expect
the improved metabolic control during pump therapy will be especially evident in patients
with more severe forms of hypoparathyrodism where there is an unmet need for improved
therapy.
Prior studies (92-CH-0011) have been important in establishing synthetic human parathyroid
hormone 1-34 (PTH) as a beneficial treatment for hypoparathyroidism, superior to conventional
therapy with calcium and calcitriol. We are conducting a randomized crossover study comparing
twice-daily subcutaneous injections vs. PTH pump therapy. We hypothesize that pump delivery
of PTH 1-34, compared to twice-daily administration, will provide smoother metabolic control
of serum mineral levels and normalization of urine mineral excretion. The two arms will be
divided into an inpatient and an outpatient phase. There will be three inpatient admissions,
baseline, 3 months, and 6 months. Subjects will be randomized to either pump therapy or to
twice daily injections at the beginning of the study and will cross over to the alternate PTH
delivery system (injections vs. pump) at the conclusion of the initial 3-month treatment
period.
Patients between 10 and 70 years of age who have had chronic hypoparathyroidism for at least
1 year may be eligible for this study. Participants have two 10- 12-day hospital admissions
and one 5-day admission. The first two inpatient admissions are separated by 3-month
outpatient periods. Outpatient monitoring will require weekly blood tests and monthly urine
tests to monitor mineral levels. After third hospital admission, patients will be placed on
conventional therapy.
hormone 1-34 (PTH) as a beneficial treatment for hypoparathyroidism, superior to conventional
therapy with calcium and calcitriol. We are conducting a randomized crossover study comparing
twice-daily subcutaneous injections vs. PTH pump therapy. We hypothesize that pump delivery
of PTH 1-34, compared to twice-daily administration, will provide smoother metabolic control
of serum mineral levels and normalization of urine mineral excretion. The two arms will be
divided into an inpatient and an outpatient phase. There will be three inpatient admissions,
baseline, 3 months, and 6 months. Subjects will be randomized to either pump therapy or to
twice daily injections at the beginning of the study and will cross over to the alternate PTH
delivery system (injections vs. pump) at the conclusion of the initial 3-month treatment
period.
Patients between 10 and 70 years of age who have had chronic hypoparathyroidism for at least
1 year may be eligible for this study. Participants have two 10- 12-day hospital admissions
and one 5-day admission. The first two inpatient admissions are separated by 3-month
outpatient periods. Outpatient monitoring will require weekly blood tests and monthly urine
tests to monitor mineral levels. After third hospital admission, patients will be placed on
conventional therapy.
- INCLUSION CRITERIA:
This study will include patients of both genders (ages 7-70) with biochemically confirmed
chronic hypoparathyroidism of at least one year duration. Twenty-four subjects will be
enrolled.
EXCLUSION CRITERIA:
Subjects who meet any of the following criteria are not eligible for the study:
- Pregnancy
- Patients who are calcium infusion dependent and/or do not respond to calcitriol
therapy to maintain normal levels of serum calcium will be excluded.
- Seizure disorder requiring antiepileptic medications.
We found this trial at
1
site
9000 Rockville Pike
Bethesda, Maryland 20892
Bethesda, Maryland 20892
Click here to add this to my saved trials
